All In Biotech

Drug Trial Radar · NCT01093729

A Study of HM11260C in Healthy Male Subject

A Dose Block-randomized, Double-blind, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM11260C After Subcutaneous Administration in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Feb 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Feb 2010

Primary completion

Oct 2010

Study completion Oct 2010

Sponsor

Sponsor type
Industry
First posted
Mar 26, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Male only, from 20 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study Design: Randomized, double-blind, placebo-controlled, escalating single-dose design. Five ascending dose cohorts are planned.

Conditions

  • Healthy

Interventions

  • HM11260CDrug

    HM11260C 0.5mcg/kg or Placebo

  • HM11260CDrug

    HM11260C 2mcg/kg or Placebo

  • HM11260CDrug

    HM11260C 4mcg/kg or Placebo

  • HM11260CDrug

    HM11260C 8mcg/kg or Placebo

  • HM11260CDrug

    HM11260C 14mcg/kg or Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SafetyTime frame: 1, 2, 3, 4, 5, 7, 9, 16, 22, 30, 36, 43, 57, 84 Day

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.